Rates of MRD negativity
| . | POLLUX . | CASTOR . | ||||
|---|---|---|---|---|---|---|
| MRD negativity (10−5) in RRMM . | D-Rd . | Rd . | P value* . | D-Vd . | Vd . | P value* . |
| ITT | ||||||
| Number evaluable | 286 | 283 | 251 | 247 | ||
| Rate | 93 (32.5%) | 19 (6.7%) | <.0001 | 38 (15.1%) | 4 (1.6%) | <.0001 |
| ≥CR | ||||||
| Number evaluable | 162 | 65 | 72 | 23 | ||
| Rate | 93 (57.4%) | 19 (29.2%) | .0001 | 38 (52.8%) | 4 (17.4%) | .0035 |
| ≤2 PL, ITT | ||||||
| Number evaluable | 234 | 226 | 192 | 187 | ||
| Rate | 77 (32.9%) | 19 (8.4%) | <.0001 | 35 (18.2%) | 3 (1.6%) | <.0001 |
| ≤2 PL, ≥CR | ||||||
| Number evaluable | 135 | 56 | 67 | 22 | ||
| Rate | 77 (57.0%) | 19 (33.9%) | .0042 | 35 (52.2%) | 3 (13.6%) | .0023 |
| . | POLLUX . | CASTOR . | ||||
|---|---|---|---|---|---|---|
| MRD negativity (10−5) in RRMM . | D-Rd . | Rd . | P value* . | D-Vd . | Vd . | P value* . |
| ITT | ||||||
| Number evaluable | 286 | 283 | 251 | 247 | ||
| Rate | 93 (32.5%) | 19 (6.7%) | <.0001 | 38 (15.1%) | 4 (1.6%) | <.0001 |
| ≥CR | ||||||
| Number evaluable | 162 | 65 | 72 | 23 | ||
| Rate | 93 (57.4%) | 19 (29.2%) | .0001 | 38 (52.8%) | 4 (17.4%) | .0035 |
| ≤2 PL, ITT | ||||||
| Number evaluable | 234 | 226 | 192 | 187 | ||
| Rate | 77 (32.9%) | 19 (8.4%) | <.0001 | 35 (18.2%) | 3 (1.6%) | <.0001 |
| ≤2 PL, ≥CR | ||||||
| Number evaluable | 135 | 56 | 67 | 22 | ||
| Rate | 77 (57.0%) | 19 (33.9%) | .0042 | 35 (52.2%) | 3 (13.6%) | .0023 |
| . | ALCYONE† . | MAIA . | ||||
|---|---|---|---|---|---|---|
| MRD negativity (10−5) in TIE NDMM . | D-VMP . | VMP . | P value* . | D-Rd . | Rd . | P value* . |
| ITT | ||||||
| Number evaluable | 350 | 356 | 368 | 369 | ||
| Rate | 99 (28.3%) | 25 (7.0%) | <.0001 | 106 (28.8%) | 34 (9.2%) | <.0001 |
| ≥CR | ||||||
| Number evaluable | 160 | 90 | 182 | 100 | ||
| Rate | 94 (58.8%) | 25 (27.8%) | <.0001 | 106 (58.2%) | 34 (34.0%) | .0001 |
| . | ALCYONE† . | MAIA . | ||||
|---|---|---|---|---|---|---|
| MRD negativity (10−5) in TIE NDMM . | D-VMP . | VMP . | P value* . | D-Rd . | Rd . | P value* . |
| ITT | ||||||
| Number evaluable | 350 | 356 | 368 | 369 | ||
| Rate | 99 (28.3%) | 25 (7.0%) | <.0001 | 106 (28.8%) | 34 (9.2%) | <.0001 |
| ≥CR | ||||||
| Number evaluable | 160 | 90 | 182 | 100 | ||
| Rate | 94 (58.8%) | 25 (27.8%) | <.0001 | 106 (58.2%) | 34 (34.0%) | .0001 |
Data are n (%) or n. Median duration of follow-up was 54.8 months in POLLUX, 50.2 months in CASTOR, 40.1 months in ALCYONE, and 36.4 months in MAIA.
P value was calculated using Fisher exact test.
MRD data in the ITT population of ALCYONE were reported previously.19 In the ITT population, 5 patients who achieved a best response of VGPR were also MRD negative (all from the D-VMP arm of ALCYONE).